<DOC>
	<DOC>NCT01069328</DOC>
	<brief_summary>To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.</brief_summary>
	<brief_title>Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must have Stage IIIB (with malignant pleural effusions) or Stage IV histological or cytological confirmation of nonsmall cell carcinoma (excluding squamous) Age &gt;/= 18 years old Patients must have at least 1 evaluable lesion. Lesions must be evaluated by CT scan or MRI ECOG Performance Status of 0 to 1 Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose: Hemoglobin &gt;/= 9.0 g/dL White blood cell (WBC) count &gt;/= 2,500/mm3 Absolute neutrophil count (ANC) &gt;/= 1,500/mm3 Platelet count &gt;/= 100,000/mm3 Total bilirubin &lt;/= 1.5 times the upper limit of normal (ULN) ALT and AST &lt;/= 2.5 X ULN (&lt;/= 5 X ULN for patients with liver involvement) INR &lt;/= 1.5 and aPTT within normal limits Serum creatinine &lt;/= ULN or creatinine clearance (CrCl) &gt;/= 45 mL/min (CrCl = Wt (kg) x (140age)/72 x Cr level, female x 0.85) for patients with creatinine levels above institutional normal Urinalysis (UA) must show less than 1+ protein in urine, or the patient will require a repeat UA. If repeat UA shows 1+ protein or more, a 24 hour urine collection will be required and must show total protein &lt;/= 1000 mg/24 hour to be eligible Patients with squamous histology Cardiac disease: Congestive heart failure &gt; Class II NYHA; active coronary artery disease (MI more than 6 months prior to study entry is allowed); or serious cardiac ventricular arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted) Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic pressure &gt; 90 mmHg despite optimal medical management HIV infection or chronic hepatitis B or C Active clinically serious infections (&gt; Grade 2 NCICTC Version 3.0) Evidence or history of CNS disease, including primary brain tumors, seizures disorders, or any brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Lung</keyword>
	<keyword>cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>